 |
Joint Medicines Formulary |
 |
Airedale NHS Foundation Trust Airedale, Wharfedale and Craven CCG |
|
Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand. |
Useful Links |
DSU: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? (March 2019) |
Haematology and Oncology Protocols and Guidelines |
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
08.01 |
Cytotoxic drugs (0,0)
|
|

Side-effects of cytotoxic drugs (0,0)
|
|

Drugs for cytotoxic-induced side-effects
(3,0)
|
08.01.01 |
Alkylating drugs
(4,0)
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(6,0)
|
08.01.03 |
Antimetabolites
(11,0)
|
08.01.04 |
Vinca alkaloids and etoposide
(4,0)
|
08.01.05 |
Other antineoplastic drugs
(23,0)
|
|

Amsacrine (0,0)
|
|

Arsenic trioxide (0,0)
|
|

Bevacizumab
(1,0)
|
|

Bexarotene (0,0)
|
|

Bortezomib
(3,0)
|
|

Cetuximab
(1,0)
|
|

Crisantaspase (0,0)
|
|

Dacarbazine and Temozolomide
(1,0)
|
|

Hydroxycarbamide
(1,0)
|
|

Ipilimumab (0,0)
|
|

Mitotane (0,0)
|
|

Panitumumab
(1,0)
|
|

Pentostatin (0,0)
|
|

Platinum compounds
(3,0)
|
|

Porfimer sodium and temoporfin (0,0)
|
|

Procarbazine
(1,0)
|
|

Protein kinase inhibitors
(21,0)
|
|

Taxanes
(3,0)
|
|

Topoisomerase I inhibitors
(2,0)
|
|

Trabectedin (0,0)
|
|

Trastuzumab
(2,0)
|
|

Tretinoin (0,0)
|
08.02 |
Drugs affecting the immune response (0,0)
|
|

Immunosuppressant therapy (0,0)
|
08.02.01 |
Antiproliferative immunosuppressants
(2,0)
|
08.02.02 |
Corticosteroids and other immunosuppressants
(2,0)
|
08.02.03 |
Rituximab and alemtuzumab
(3,0)
|
08.02.04 |
Other immunomodulating drugs
(5,0)
|
|

Interferon Alfa
(2,0)
|
|

Interferon beta (0,0)
|
|

Aldesleukin (0,0)
|
|

Glatiramer acetate (0,0)
|
|

Natalizumab (0,0)
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
08.03.01 |
Oestrogens
(2,0)
|
08.03.02 |
Progestogens
(2,0)
|
08.03.03 |
Androgens (0,0)
|
08.03.04 |
Hormone antagonists (0,0)
|
08.03.04.01 |
Breast cancer
(5,0)
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(1,0)
|
|

Gonadorelin analogues (0,0)
|
|

Anti-androgens
(5,0)
|
08.03.04.03 |
Somatostatin analogues
(2,0)
|
|
|
|